Center for Healthcare Supply Chain Research and AACP partnering on specialty pharmacy educational tool
ARLINGTON, Va. — The Center for Healthcare Supply Chain Research, HDMA’s non-profit research foundation, and the American Association of Colleges of Pharmacy, the national organization representing the interests of pharmacy education, are partnering to provide the nation’s schools of pharmacy a supply chain educational tool surrounding the distribution of specialty pharmaceuticals. This teaching resource was released Thursday in conjunction with a webinar jointly hosted by the Center and AACP. The webinar was made possible through the support of the Cardinal Health Foundation.
This turn-key presentation, titled, “Understanding Specialty Distribution,” outlines characteristics of the specialty pharmaceutical sector, one of the fastest-growing markets in the healthcare industry. The resource, sponsored by Eisai, provides Center data on the processes supporting the movement of medication from the manufacturer (as a finished product) to the customer (including pharmacies, hospitals and clinics).
The PowerPoint deck can also be used by manufacturer, distributor and pharmacy presenters/trainers to "on board" new personnel, and, through the partnership with AACP, to train student pharmacists. Additionally, a "notes" feature provides speaking points for each slide and allows the presenter to customize each presentation to their audience’s needs.
“This program provides a comprehensive overview of the specialty supply chain, with rich descriptions of the important stakeholder relationships, the economics of bringing specialty products to market and regulatory influences on this unique supply chain,” stated Karen Ribler, EVP and COO of the Center for Healthcare Supply Chain Research. “We are grateful to Eisai and the Cardinal Health Foundation for supporting this resource, and pleased to partner with AACP to help educate America’s future pharmacists on the mechanics of the specialty supply chain.”
In 2013, the Center partnered with AACP to release “Understanding Distribution,” a curriculum on the processes surrounding the distribution of traditional pharmaceuticals. Supported by a grant from the Cardinal Health Foundation, this resource also was offered to more than 120 college pharmacy programs.
“AACP is aware that specialty pharmaceuticals are growing rapidly as powerful tools for patient care,” commented AACP EVP and CEO Lucinda Maine. “Today’s students will be practicing pharmacy well into the middle of this century and must be equipped with the information on supply chain management contained in this valuable Center resource.”
DSNTV: Chasing — and engaging — today’s elusive consumer
BY DSN STAFF
Retailers and suppliers need to work harder to find creative ways to better engage today’s “elusive” consumer and motivate her to want to make a trip to the store, Lisa Paley, chief customer officer for Pfizer Consumer Healthcare, told Drug Store News for the latest edition of DSNTV Executive Viewpoint video interview series.
“The consumer is a little elusive right now,” Paley explained. “They’re in control, but they’re not as identifiable: they’re doing a lot [online] pre-shop before they come to the store; they’re buying online; they’re buying [in] brick and mortar, so they’re a little hard to track and a little harder to engage to want to make the trip into the store.”
GSK working toward Ebola vaccine by end of 2014
LONDON — GlaxoSmithKline expects to have its Ebola vaccine available by year's end, CEO and executive director Andew Witty told analysts during the company's third-quarter conference call Wednesday.
"Given the apparent health emergency, we are leaving no stone unturned in this project," he said. "And if all goes well, I fully expect GSK to be the first company in a position to make a vaccine available to health agencies and governments hopefully, toward the end of 2014."
Both GSK and Johnson & Johnson are working toward providing an Ebola vaccine sooner than later.
Johnson & Johnson on Wednesday announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. Janssen is targeting production of more than one million doses of the vaccine regimen in 2015, 250,000 of which are expected to be released for broad application in clinical trials by May 2015.
Loading Post Please Wait...